[1]
|
C. P. Kovesdy, S. Ahmadzadeh, J. E. Anderson and K. Kalantar-Zadeh, “Secondary Hyperparathyroidism is Associated with Higher Mortality in Men with Moderate to Severe Chronic Kidney Disease,” Kidney International, Vol. 73, No. 11, 2008, pp. 1296-1302.
doi:10.1038/ki.2008.64
|
[2]
|
G. M. Chertow, P. Raggi, S. Chasan-Taber, J. Bommer, H. Holzer and S. K. Burke, “Determinants of Progressive Vascular Calcification in Haemodialysis Patients,” Nephrology Dialysis Transplantation, Vol. 19, No. 6, 2004, pp. 1489-1496. doi:10.1093/ndt/gfh125
|
[3]
|
K. A. Lomashvili, P. Garg, S. Narisawa, J. L. Millan and W. C. O’Neill, “Upregulation of Alkaline Phosphatase and Pyrophosphate Hydrolysis: Potential Mechanism for Uremic Vascular Calcification,” Kidney International, Vol. 73, No. 9, 2008, pp. 1024-1030.
doi:10.1038/ki.2008.26
|
[4]
|
K. Kalantar-Zadeh, N. Kuwae, D. L. Regidor, et al., “Survival Predictability of Time-Varying Indicators of Bone Disease in Maintenance Hemodialysis Patients,” Kidney International, Vol. 70, No. 4, 2006, pp. 771-780.
doi:10.1038/sj.ki.5001514
|
[5]
|
S. Beddhu, B. Baird, X. Ma, A. K. Cheung and T. Greene, “Serum Alkaline Phosphatase and Mortality in Hemodialysis Patients,” Clinical Nephrology, Vol. 74, No. 2, 2010, pp. 91-96.
|
[6]
|
M. Schoppet and C. M. Shanahan, “Role for Alkaline Phosphatase as an Inducer of Vascular Calcification in Renal Failure?” Kidney International, Vol. 73, No. 9, 2008, pp. 989-991. doi:10.1038/ki.2008.104
|
[7]
|
P. Magnusson, C. A. Sharp, M. Magnusson, J. Risteli, M. W. Davie and L. Larsson, “Effect of Chronic Renal Failure on Bone Turnover and Bone Alkaline Phosphatase Isoforms,” Kidney International, Vol. 60, No. 1, 2001, pp. 257-265. doi:10.1046/j.1523-1755.2001.00794.x
|
[8]
|
S. Fletcher, R. G. Jones, H. C. Rayner, et al., “Assessment of Renal Osteodystrophy in Dialysis Patients: Use of Bone Alkaline Phosphatase, Bone Mineral Density and Parathyroid Ultrasound in Comparison with Bone Histology,” Nephron, Vol. 75, No. 4, 1997, pp. 412-419.
|
[9]
|
M. Reslerova and S. M. Moe, “Vascular Calcification in Dialysis Patients: Pathogenesis and Consequences,” American Journal of Kidney Disease, Vol. 41, No. 3, pp. S96-S99. doi:10.1053/ajkd.2003.50094
|
[10]
|
S. Narisawa, D. Harmey, M. C. Yadav, W. C. O’Neill, M. F. Hoylaerts and J. L. Millan, “Novel Inhibitors of Alkaline Phosphatase Suppress Vascular Smooth Muscle Cell Calcification,” Journal of Bone Mineral Research, Vol. 22, No. 11, 2007, pp. 1700-1710.
doi:10.1359/jbmr.070714
|
[11]
|
G. P. Fadini, P. Pauletto, A. Avogaro and M. Rattazzi, “The Good and the Bad in the Link between Insulin Resistance and Vascular Calcification,” Atherosclerosis, Vol. 193, No. 2, 2007, pp. 241-244.
|
[12]
|
M. K. Sigrist, M. W. Taal, P. Bungay and C. W. McIntyre, “Progressive Vascular Calcification over 2 Years Is Associated with Arterial Stiffening and Increased Mortality in Patients with Stages 4 and 5 Chronic Kidney Disease,” Clinical Journal of American Society of Nephrology, Vol. 2, No. 6, 2007, pp. 1241-1248.
doi:10.2215/CJN.02190507
|
[13]
|
M. J. Blayney, R. L. Pisoni, J. L. Bragg-Gresham, et al., “High Alkaline Phosphatase Levels in Hemodialysis Patients are Associated with Higher Risk of Hospitalization and Death,” Kidney International, Vol. 74, No. 5, 2008, pp. 655-663. doi:10.1038/ki.2008.248
|
[14]
|
D. L. Regidor, C. P. Kovesdy, R. Mehrotra R, et al., “Serum Alkaline Phosphatase Predicts Mortality among Maintenance Hemodialysis Patients,” Journal of American Society of Nephrology, Vol. 19, No. 11, 2008, pp. 2193-2203. doi:10.1681/ASN.2008010014
|
[15]
|
A. Kerner, O. Avizohar, R. Sella, et al., “Association between Elevated Liver Enzymes and C-reactive Protein: Possible Hepatic Contribution to Systemic Inflammation in the Metabolic Syndrome,” Arteriosclerosis Thrombosis Vascular Biology, Vol. 25, No. 1, 2005, pp. 193-197.
|
[16]
|
B. M. Cheung, K. L. Ong, R. V. Cheung, et al., “Association between Elevated Liver Enzymes and C-reactive Protein in Hong Kong Chinese,” Clinical Chemistry and Laboratory Medicine, Vol. 46, No. 4, 2008, pp. 523-527.
doi:10.1515/CCLM.2008.111
|
[17]
|
E. G. Lowrie and N. L. Lew, “Death Risk in Hemodialysis Patients: The Predictive Value of Commonly Measured Variables and an Evaluation of Death Rate Differences between Facilities,” American Journal of Kidney Disease, Vol. 15, No. 5, 1990, pp. 458-482.
|
[18]
|
J. Zimmermann, S. Herrlinger, A. Pruy, T. Metzger and C. Wanner, “Inflammation Enhances Cardiovascular Risk and Mortality in Hemodialysis Patients,” Kidney Internation, Vol. 55, No. 2, 1999, pp. 648-658.
|
[19]
|
J. Y. Yeun, R. A. Levine, V. Mantadilok and G. A. Kaysen, “C-Reactive Protein Predicts All Cause and Cardiovascular Mortality in Hemodialysis Patients,” American Journal Kidney Disease, Vol. 35, No. 3, 2000, pp. 469- 476. doi:10.1016/S0272-6386(00)70200-9
|